
The panel explains how to weigh safety and efficacy near kidney function dosing thresholds and how pharmacists can work with informatics teams to build BSA-adjusted estimated glomerular filtration rate (eGFR) into the electronic health record (EHR).

Gillian McGovern is an editor at Pharmacy Times®. She graduated from Rowan University in 2023 with a BA in Writing Arts and concentrations in Publishing & Writing for the Public, Technical & Professional Writing, and Creative Writing.

The panel explains how to weigh safety and efficacy near kidney function dosing thresholds and how pharmacists can work with informatics teams to build BSA-adjusted estimated glomerular filtration rate (eGFR) into the electronic health record (EHR).

A panel of pharmacists explain how to bridge estimated creatinine clearance and the race-free CKD-EPI eGFR in dosing decisions while the field moves toward contemporary kidney function equations.

Heart failure with preserved ejection fraction (HFpEF) is often missed in primary care, and pharmacists can close care gaps by optimizing GDMT, including the nonsteroidal MRA finerenone.

Moving medical cannabis to Schedule III may expand research and access, but pharmacists need to be ready to counsel patients on drug interactions, cannabis use disorder, and psychiatric risks.

Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.

Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.

Panelists explain how health systems can use the National Kidney Foundation’s CKDintercept initiative to build interdisciplinary, value-based kidney care, starting with small patient groups and setting time-bound treatment goals.

The cardiovascular-kidney-metabolic (CKM) framework can replace siloed care with comanagement across specialties, centered on an engaged patient and supported by making fuller use of clinical pharmacists.

The cardiovascular-kidney-metabolic framework puts the urine albumin-to-creatinine ratio at the center of risk stratification, so that a positive result leads to earlier treatment rather than just being documented.

A panel of 4 health care professionals describe how their health systems adopted the race-free 2021 CKD-EPI equations.

Two authors of new multidisciplinary consensus recommendations explain how clinical pharmacists speed thrombolytic and reversal agent administration in acute stroke.

A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.

Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.

Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.

The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.

This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.

The approval is supported by data from the phase 3 FINE-ONE clinical trial.

As centanafadine awaits DEA scheduling, Megan Maroney, PharmD, BCPP, FAAPP, and Danielle Stutzman, PharmD, BCPP, unpack what its modest efficacy data, favorable interaction profile, and pediatric dosing considerations mean for real-world ADHD prescribing.

Maroney and her guest, Danielle Stutzman, PharmD, BCPP, break down efficacy data and potential advantages of centanafadine, the newly approved triple reuptake inhibitor for ADHD.

A 5-level model for classifying AI-enabled pharmacy systems may help health systems advance to new levels of pharmacy autonomy.

This episode covers the importance of considering vaccine timing, selection, and hesitancy in patients on immunomodulating and immunosuppressive therapies, along with emerging data linking several vaccines to reduced dementia risk.

Melissa Seifert, PharmD, of UPMC Health Plan, explains how managed care pharmacists guide DMT selection and address adherence barriers in patients with MS.

A clinical pharmacy specialist at UPMC Health Plan discusses how pharmacists help select disease-modifying therapies, address adherence barriers, and coordinate whole-person care for those with MS.

The podcast will cover relevant areas in psychiatry, new literature and clinical data, new drugs, and other topics that are coming down the pipeline.

In this new show, host Megan Maroney, PharmD, BCPP, FAAPP, will examine therapies, trends, and clinical decisions shaping care for psychiatric conditions.

The approval is supported by clinical data from 2 studies.

The therapy is administered via an intratumoral injection every 2 weeks for 8 consecutive doses.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses how pharmacists can layer mediator-symptom management with cytoreductive or targeted therapy in systemic mastocytosis (SM) and interdisciplinary communication.